Liquid Biopsy Market Size by Applications, by Type, by End-User, by Deployment & by Technology 2032
Global Liquid Biopsy Market was valued at USD 0.9 Billion in 2022 and is projected to reach USD 2.2 Billion by 2030, growing at a CAGR of 12.1% from 2024 to 2030.
The Liquid Biopsy Market is poised to revolutionize the way we diagnose and treat various diseases, including cancer. Unlike traditional biopsy methods that require tissue samples, liquid biopsy uses blood samples to detect cancer-related genetic mutations, providing a minimally invasive alternative. With advancements in technology and an increased focus on early diagnosis, the liquid biopsy market has gained significant traction in recent years. Liquid biopsy is a diagnostic tool that analyzes circulating tumor DNA (ctDNA), exosomes, or other tumor-related markers found in the blood. It is particularly beneficial for patients with hard-to-reach tumors or those who are not candidates for traditional biopsy procedures. This market is experiencing rapid growth, fueled by its potential for early detection, real-time monitoring, and personalized treatment options. Key players in the liquid biopsy market include companies like Guardant Health, Roche, and Biocept, all of which are investing heavily in R&D to improve accuracy and expand applications beyond oncology. The technology is being adapted for various types of cancer, including lung, breast, and colon cancer, with promising results in clinical trials. Furthermore, the increasing demand for non-invasive diagnostic techniques and the rising prevalence of cancer globally are significant drivers of the liquid biopsy market. According to a report, the market is expected to reach USD 10.5 billion by 2028, growing at a CAGR of 20.6%. Governments and healthcare organizations are also increasing their focus on liquid biopsy as part of broader efforts to improve early cancer detection and treatment. The future of liquid biopsy is bright, with continuous innovations and growing adoption among healthcare providers. As more clinical evidence emerges and technology improves, liquid biopsy could become the gold standard for non-invasive cancer diagnosis and monitoring, significantly enhancing patient outcomes.
Get an In-Depth Research Analysis of the Global Liquid Biopsy Market Size And Forecast [2025-2032]
Who are the largest Global manufacturers in the Liquid Biopsy industry?
- Biocept
- Qiagen
- Roche Diagnostics
- Bio-Rad Laboratories
- Myriad Genetics
- Menarini-Silicon Biosystems
- Trovagene
- Guardant Health
- Mdxhealth
- Genomic Health
- Raindance Technologies
- Thermo Fisher Scientific
- Illumina
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Liquid Biopsy Market Size And Forecast [2025-2032]
What are the factors driving the growth of the Global Liquid Biopsy Market?
Growing demand for below applications around the world has had a direct impact on the growth of the Global Liquid Biopsy Market
- Reference Laboratory
- The Hospital
- Research Center
- Other
What are the types of Liquid Biopsy available in the Market?
Based on Types the Market is categorized into Below types that held the largest Liquid Biopsy market share In 2023.
- Test Suite
- Equipment
- Service
Which regions are leading the Global Liquid Biopsy Market?
- Global (United States, Global and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Global, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia, etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Liquid Biopsy Market Research Analysis
Detailed TOC of Global Liquid Biopsy Market Research Report, 2024-2032
1. Introduction of the Global Liquid Biopsy Market
- Overview of the Market
- Scope of Report
- Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
- Data Mining
- Validation
- Primary Interviews
- List of Data Sources
4. Global Liquid Biopsy Market Outlook
- Overview
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porters Five Force Model
- Value Chain Analysis
5. Global Liquid Biopsy Market, By Type
6. Global Liquid Biopsy Market, By Application
7. Global Liquid Biopsy Market, By Geography
- Global
- Europe
- Asia Pacific
- Rest of the World
8. Global Liquid Biopsy Market Competitive Landscape
- Overview
- Company Market Ranking
- Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768